Musculoskeletal System Disorders Market Research Report Information By Type (Rheumatoid Arthritis, Osteoarthritis, Osteoporosis, Psoriatic Arthritis, Ankylosing Spondylitis), Treatment (Biologics, Corticosteroids, Physical Therapy, Protein Therapy, Composite Grafts) and End User (Hospitals and Clinics, Ambulatory Surgical Centers) - Forecast to 2032

Table of Contents

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

Chapter 5. Market Factor Analysis

5.1 Porters Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

Chapter 6. Global Musculoskeletal System Disorders Market, by Type

6.1 Introduction

6.2 Rheumatoid Arthritis

6.3 Osteoarthritis

6.4 Osteoporosis

6.5 Psoriatic Arthritis

6.6 Ankylosing Spondylitis

6.7 Fibromyalgia

6.8 Others

Chapter 7. Global Musculoskeletal System Disorders Market, by Treatment

7.1 Introduction

7.2 Biologics

7.3 Corticosteroids

7.4 Physical Therapy

7.5 Extracorporeal Shock Wave Therapy

7.6 Protein Therapy

7.7 Synthetic Bone Graft

7.8 Composite Grafts

7.9 Demineralized Bone Matrix

7.10 Others

Chapter 9. Global Musculoskeletal System Disorders Market, by End User

9.1 Introduction

9.2 Hospitals & Clinics

9.3 Ambulatory Surgical Centers

9.4 Others

Chapter 10. Global Musculoskeletal System Disorders Market, by Region

10.1 Introduction

10.2 Americas

10.2.1 North America

10.2.1.1 US

10.2.1.2 Canada

10.2.2 Latin America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 Italy

10.3.1.4 Spain

10.3.1.5 UK

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia-Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 South Korea

10.4.6 Rest of Asia-Pacific

10.5 Middle East & Africa

Chapter 11. Competitive Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Developments & Strategies

11.3.1 Key Developments

Chapter 12 Company Profiles

12.1 AB Science

12.1.1. Company Overview

12.1.2. Financial Overview

12.1.3. Treatments Offered

12.1.4. Key Developments

12.1.5. SWOT Analysis

12.1.6. Key Strategies

12.2 AbGenomics International, Inc.

12.2.1 Company Overview

12.2.2 Financial Overview

12.2.3 Treatments Offered

12.2.4 Key Developments

12.2.5 SWOT Analysis

12.2.6 Key Strategies

12.3 Alder Biopharmaceuticals, Inc.

12.3.1 Company Overview

12.3.2 Financial Overview

12.3.3 Treatments Offered

12.3.4 Key Developments

12.3.5 SWOT Analysis

12.3.6 Key Strategies

12.4 Amgen Inc.

12.4.1 Company Overview

12.4.2 Financial Overview

12.4.3 Treatments Offered

12.4.4 Key Developments

12.4.5 SWOT Analysis

12.4.5 Key Strategies

12.5 Lexicon Pharmaceuticals, Inc.

12.5.1 Company Overview

12.5.2 Financial Overview

12.5.3 Treatments Offered

12.5.4 Key Developments

12.5.5 SWOT Analysis

12.5.6 Key Strategies

12.6 LG Chem

12.6.1 Company Overview

12.6.2 Financial Overview

12.6.3 Treatments Offered

12.6.4 Key Developments

12.6.5 SWOT Analysis

12.6.6 Key Strategies

12.7 OrthoTrophix, Inc.

12.7.1 Company Overview

12.7.2 Financial Overview

12.7.3 Treatments Offered

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.7.6 Key Strategies

12.8 Tarsa Therapeutics, Inc.

12.8.1 Company Overview

12.8.2 Financial Overview

12.8.3 Treatments Offered

12.8.4 Key Developments

12.8.5 SWOT Analysis

12.8.6 Key Strategies

12.9 PhytoHealth Corporation

12.9.1 Company Overview

12.9.2 Financial Overview

12.9.3 Treatments Offered

12.9.4 Key Developments

12.9.5 SWOT Analysis

12.9.6 Key Strategies

12.10 Eisai Co., Ltd.

12.10.1 Company Overview

12.10.2 Financial Overview

12.10.3 Treatments Offered

12.10.4 Key Developments

12.10.5 SWOT Analysis

12.10.6 Key Strategies

12.11 Astellas Pharma Inc

12.11.1 Company Overview

12.11.2 Financial Overview

12.11.3 Treatments Offered

12.11.4 Key Developments

12.11.5 SWOT Analysis

12.11.5 Key Strategies

12.12 AstraZeneca

12.12.1 Company Overview

12.12.2 Financial Overview

12.12.3 Treatments Offered

12.12.4 Key Developments

12.12.5 SWOT Analysis

12.12.6 Key Strategies

12.13 Baxter

12.13.1 Company Overview

12.13.2 Financial Overview

12.13.3 Treatments Offered

12.13.4 Key Developments

12.13.5 SWOT Analysis

12.13.6 Key Strategies

12.14 GlaxoSmithKline PLC

12.14.1 Company Overview

12.14.2 Financial Overview

12.14.3 Treatments Offered

12.14.4 Key Developments

12.14.5 SWOT Analysis

12.14.6 Key Strategies

12.15 Others

Chapter 13. Appendix

13.1. References

13.2. Related Reports

LIST OF TABLES

Table 1 Global Musculoskeletal System Disorders Synopsis, 2020-2027

Table 2 Global Musculoskeletal System Disorders Market Estimates & Forecast, 2020-2027, (USD Million)

Table 3 Global Musculoskeletal System Disorders Market, by Region, 2020-2027(USD Million)

Table 4 Global Musculoskeletal System Disorders Market, by Type, 2020-2027(USD Million)

Table 5 Global Musculoskeletal System Disorders Market, by Treatment, 2020-2027(USD Million)

Table 6 Global Musculoskeletal System Disorders Market, by End User, 2020-2027(USD Million)

Table 7 Americas: Musculoskeletal System Disorders Market, by Type, 2020-2027(USD Million)

Table 8 Americas: Musculoskeletal System Disorders Market, by Treatment, 2020-2027(USD Million)

Table 9 Americas: Musculoskeletal System Disorders Market, by End User, 2020-2027(USD Million)

Table 10 Americas: Musculoskeletal System Disorders Market, by Region, 2020-2027(USD Million)

Table 11 North America: Musculoskeletal System Disorders Market, by Type, 2020-2027(USD Million)

Table 12 North America: Musculoskeletal System Disorders Market, by Treatment, 2020-2027(USD Million)

Table 13 North America: Musculoskeletal System Disorders Market, by End User, 2020-2027(USD Million)

Table 14 Latin America: Musculoskeletal System Disorders Market, by Type, 2020-2027(USD Million)

Table 15 Latin America: Musculoskeletal System Disorders Market, by Treatment, 2020-2027(USD Million)

Table 16 Latin America: Musculoskeletal System Disorders Market, by End User, 2020-2027(USD Million)

Table 17 Europe: Musculoskeletal System Disorders Market, by Type, 2020-2027(USD Million)

Table 18 Europe: Musculoskeletal System Disorders Market, by Treatment, 2020-2027(USD Million)

Table 19 Europe: Musculoskeletal System Disorders Market, by End User, 2020-2027(USD Million)

Table 20 Europe: Musculoskeletal System Disorders Market, by Region, 2020-2027(USD Million)

Table 21 Western Europe: Musculoskeletal System Disorders Market, by Type, 2020-2027(USD Million)

Table 22 Western Europe: Musculoskeletal System Disorders Market, by Treatment, 2020-2027(USD Million)

Table 23 Western Europe: Musculoskeletal System Disorders Market, by End User, 2020-2027(USD Million)

Table 24 Eastern Europe: Musculoskeletal System Disorders Market, by Type, 2020-2027(USD Million)

Table 25 Eastern Europe: Musculoskeletal System Disorders Market, by Treatment, 2020-2027(USD Million)

Table 26 Eastern Europe: Musculoskeletal System Disorders Market, by End User, 2020-2027(USD Million)

Table 27 Asia-Pacific: Musculoskeletal System Disorders Market, by Type, 2020-2027(USD Million)

Table 28 Asia-Pacific: Musculoskeletal System Disorders Market, by Treatment, 2020-2027(USD Million)

Table 29 Asia-Pacific: Musculoskeletal System Disorders Market, by End User, 2020-2027(USD Million)

Table 30 Middle East & Africa: Musculoskeletal System Disorders Market, by Type, 2020-2027(USD Million)

Table 31 Middle East & Africa: Musculoskeletal System Disorders Market, by Treatment, 2020-2027(USD Million)

Table 32 Middle East & Africa: Musculoskeletal System Disorders Market, by End User, 2020-2027(USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation of the Global Musculoskeletal System Disorders Market

Figure 3 Market Dynamics for the Global Musculoskeletal System Disorders Market

Figure 4 Global Musculoskeletal System Disorders Market Share, by Type, 2020

Figure 5 Global Musculoskeletal System Disorders Market Share, by Treatment, 2020

Figure 6 Global Musculoskeletal System Disorders Market Share, by End User, 2020

Figure 7 Global Musculoskeletal System Disorders Market Share, by Region, 2020

Figure 8 Americas: Musculoskeletal System Disorders Market Share, by Region, 2020

Figure 9 North America: Musculoskeletal System Disorders Market Share, by Country, 2020

Figure 10 Latin America: Musculoskeletal System Disorders Market Share, by Country, 2020

Figure 11 Europe: Musculoskeletal System Disorders Market Share, by Country, 2020

Figure 12 Asia-Pacific: Musculoskeletal System Disorders Market Share, by Country, 2020

Figure 13 Middle East & Africa: Musculoskeletal System Disorders Market Share, by Country, 2020

Figure 14 Global Musculoskeletal System Disorders Market: Company Share Analysis, 2020 (%)

Figure 15 AB Science: Key Financials

Figure 16 AB Science: Segmental Revenue

Figure 17 AB Science: Regional Revenue

Figure 18 AbGenomics International: Key Financials

Figure 19 AbGenomics International: Segmental Revenue

Figure 20 AbGenomics International: Regional Revenue

Figure 21 Alder BioPharmaceuticals: Key Financials

Figure 22 Alder BioPharmaceuticals: Segmental Revenue

Figure 23 Alder BioPharmaceuticals: Regional Revenue

Figure 24 Amgen: Key Financials

Figure 25 Amgen: Segmental Revenue

Figure 26 Amgen: Regional Revenue

Figure 27 Lexicon Pharmaceuticals: Key Financials

Figure 28 Lexicon Pharmaceuticals: Regional Revenue

Figure 29 Lexicon Pharmaceuticals: Key Financials

Figure 30 LG Life Sciences: Segmental Revenue

Figure 31 LG Life Sciences: Regional Revenue

Figure 32 LG Life Sciences: Key Financials

Figure 33 OrthoTrophix: Segmental Revenue

Figure 34 OrthoTrophix: Regional Revenue

Figure 35 OrthoTrophix: Key Financials

Figure 36 Tarsa Therapeutics: Segmental Revenue

Figure 37 Tarsa Therapeutics: Regional Revenue

Figure 38 Tarsa Therapeutics: Key Financials

Figure 39 PhytoHealth Corporation: Segmental Revenue

Figure 40 PhytoHealth Corporation: Regional Revenue

Figure 41 PhytoHealth Corporation: Key Financials

Figure 42 Eisai Co., Ltd.: Segmental Revenue

Figure 43 Eisai Co., Ltd.: Regional Revenue

Figure 44 Eisai Co., Ltd.: Key Financials

Figure 45 Astellas Pharma Inc : Segmental Revenue

Figure 46 Astellas Pharma Inc : Regional Revenue

Figure 47 Astellas Pharma Inc : Key Financials

Figure 48 AstraZeneca: Segmental Revenue

Figure 49 AstraZeneca: Regional Revenue

Figure 50 AstraZeneca: Key Financials

Figure 51 Baxter International : Segmental Revenue

Figure 52 Baxter International : Regional Revenue

Figure 53 Baxter International : Key Financials

Figure 54 GlaxoSmithKline plc: Segmental Revenue

Figure 55 GlaxoSmithKline plc: Regional Revenue

Figure 56 GlaxoSmithKline plc: Key Financials